News | 29 May 2026
AbbVie wins FDA nod for DECNUPAZ in rare blood cancer
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
Under the new initiative, each company takes on a defined role across the recycling chain
PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion
For the full year, standalone gross revenue crossed Rs. 1,700 crore
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
The company highlighted continued demand strength and pricing resilience despite global disruptions
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
The move signals a major expansion milestone for the Swiss laboratory automation company
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Fresh data from the State of the World’s Nursing 2025 report shows the global nursing workforce has expanded from 27.9 million in 2018 to 29.8 million in 2023
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
Revenue from operations climbed 13% to Rs. 886.87 crore
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
Subscribe To Our Newsletter & Stay Updated
